“Wayne has a solid foundation of experience in clinical trial management and was a dedicated employee. He is action-oriented and showed effective leadership skills in his assigned tasks while at Novartis. He is aware of the “big picture”, always strove to meet key deliverables and milestones in an efficient and timely manner. Good communication skills, builds & fosters effective customer relationships; strong team focus and a great sense of humor. A strategic thinker and a straight shooter, Wayne is never afraid to point out potential risks and offer ideas for how to work around them.”
Activity
-
Friday, April 26th, was my last day at Amgen, Inc. I will miss my Horizon colleagues that are still with Amgen and those that have moved on too! The…
Friday, April 26th, was my last day at Amgen, Inc. I will miss my Horizon colleagues that are still with Amgen and those that have moved on too! The…
Liked by Wayne Hull
-
Cabaletta Bio is attending the Myasthenia Gravis Foundation of America (MGFA) 2024 National Patient Conference in Tampa, FL! Come see us at booth 17…
Cabaletta Bio is attending the Myasthenia Gravis Foundation of America (MGFA) 2024 National Patient Conference in Tampa, FL! Come see us at booth 17…
Liked by Wayne Hull
-
Sharing the 5th essay in my Endpoint News series on parallels between thru hiking the PCT and cancer R&D. This one focuses on the story behind the…
Sharing the 5th essay in my Endpoint News series on parallels between thru hiking the PCT and cancer R&D. This one focuses on the story behind the…
Liked by Wayne Hull
Publications
-
Phase 1 Expansion Study of an Oral TORC1/TORC2 Inhibitor (CC-223) in Non-Pancreatic Neuroendocrine Tumors (NET)
-
Clinical efficacy of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic NET. CC-223, an ATP-competitive inhibitor of the mTOR kinase, inhibits both TORC1 and TORC2 complexes.
Other authors -
Honors & Awards
-
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study - NEJM
-
On April 16, 2015, the trial I was the Study Manager of, was published in NEJM:
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
Gulen Hatemi, M.D., Melike Melikoglu, M.D., Recep Tunc, M.D., Cengiz Korkmaz, M.D., Banu Turgut Ozturk, M.D., Cem Mat, M.D., Peter A. Merkel, M.D., Kenneth T. Calamia, M.D., Ziqi Liu, Ph.D., Lilia Pineda, M.D., Randall M. Stevens, M.D., Hasan Yazici, M.D., and Yusuf Yazici, M.D.
N Engl J Med 2015; 372:1510-1518April 16, 2015DOI:…On April 16, 2015, the trial I was the Study Manager of, was published in NEJM:
Apremilast for Behçet’s Syndrome — A Phase 2, Placebo-Controlled Study
Gulen Hatemi, M.D., Melike Melikoglu, M.D., Recep Tunc, M.D., Cengiz Korkmaz, M.D., Banu Turgut Ozturk, M.D., Cem Mat, M.D., Peter A. Merkel, M.D., Kenneth T. Calamia, M.D., Ziqi Liu, Ph.D., Lilia Pineda, M.D., Randall M. Stevens, M.D., Hasan Yazici, M.D., and Yusuf Yazici, M.D.
N Engl J Med 2015; 372:1510-1518April 16, 2015DOI: 10.1056/NEJMoa1408684
Recommendations received
1 person has recommended Wayne
Join now to viewMore activity by Wayne
-
Excited to kick off my Penn Med Fund today supporting early career women physicians and scientists working on Cellular Immunotherapy under Carl June…
Excited to kick off my Penn Med Fund today supporting early career women physicians and scientists working on Cellular Immunotherapy under Carl June…
Liked by Wayne Hull
-
So happy to be here at the Sarah Cannon Annual Meeting with these leaders in oncology! Thankful for being able to learn and share ideas to on how we…
So happy to be here at the Sarah Cannon Annual Meeting with these leaders in oncology! Thankful for being able to learn and share ideas to on how we…
Liked by Wayne Hull
-
We are thrilled to announce the 2024 speakers for the RARE Drug Development Symposium. Every year, we bring together the most brilliant minds and…
We are thrilled to announce the 2024 speakers for the RARE Drug Development Symposium. Every year, we bring together the most brilliant minds and…
Liked by Wayne Hull
-
Cabaletta Bio is excited to announce that the FDA has granted orphan drug designation to CABA-201 for the treatment of myositis. This designation is…
Cabaletta Bio is excited to announce that the FDA has granted orphan drug designation to CABA-201 for the treatment of myositis. This designation is…
Liked by Wayne Hull
-
On #WorldCancerDay, I stand with all those committed to achieving equal access to cancer care. The alarming upward trend in global cancer incidence…
On #WorldCancerDay, I stand with all those committed to achieving equal access to cancer care. The alarming upward trend in global cancer incidence…
Liked by Wayne Hull
-
Heartfelt emotions, our last Legacy Horizon now Amgen Pharmacovigilance team lunch as we begin new chapters. It’s been a pleasure working along side…
Heartfelt emotions, our last Legacy Horizon now Amgen Pharmacovigilance team lunch as we begin new chapters. It’s been a pleasure working along side…
Liked by Wayne Hull
-
We’re pleased to announce that the FDA has accepted for priority review a supplemental biologics license application (sBLA) for our investigational…
We’re pleased to announce that the FDA has accepted for priority review a supplemental biologics license application (sBLA) for our investigational…
Liked by Wayne Hull
-
Our Investigational New Drug application for KYV-101 has received FDA clearance for patients with treatment-refractory progressive…
Our Investigational New Drug application for KYV-101 has received FDA clearance for patients with treatment-refractory progressive…
Liked by Wayne Hull
-
Lisbon is about to become the coolest spot for breaking down the research game! Jump into the groove with Jeff Repper as he spills the beans on the…
Lisbon is about to become the coolest spot for breaking down the research game! Jump into the groove with Jeff Repper as he spills the beans on the…
Liked by Wayne Hull
-
This week, Kristen Hege came home from a 6-month journey hiking the Pacific Coast Trail from Mexico to Canada to meet with her old Early Clinical…
This week, Kristen Hege came home from a 6-month journey hiking the Pacific Coast Trail from Mexico to Canada to meet with her old Early Clinical…
Liked by Wayne Hull
-
Today, Apogee provided business updates and reported third quarter 2023 financial results. This includes our announcement of our finalized nomination…
Today, Apogee provided business updates and reported third quarter 2023 financial results. This includes our announcement of our finalized nomination…
Liked by Wayne Hull
-
The ACELYRIN team has enjoyed networking with our industry peers at the American College of Rheumatology Convergence this week in San Diego! Thank…
The ACELYRIN team has enjoyed networking with our industry peers at the American College of Rheumatology Convergence this week in San Diego! Thank…
Liked by Wayne Hull
-
Bittersweet post. Last post from Translational Medicine. Yesterday we went to new homes within Amgen or began the transition process to joining the…
Bittersweet post. Last post from Translational Medicine. Yesterday we went to new homes within Amgen or began the transition process to joining the…
Liked by Wayne Hull
-
Excited to share my thoughts on the next wave of cancer immunotherapies and SITC’s goal of enabling 100 new FDA approved treatments in this field…
Excited to share my thoughts on the next wave of cancer immunotherapies and SITC’s goal of enabling 100 new FDA approved treatments in this field…
Liked by Wayne Hull
-
A phase III study of cancer drug Tivdak from Genmab and Seagen has shown a 30% reduction in the risk of death in patients with recurrent or…
A phase III study of cancer drug Tivdak from Genmab and Seagen has shown a 30% reduction in the risk of death in patients with recurrent or…
Liked by Wayne Hull
-
I am delighted and honored to be joining the board of IGM Biosciences! https://lnkd.in/gRSuktQU
I am delighted and honored to be joining the board of IGM Biosciences! https://lnkd.in/gRSuktQU
Liked by Wayne Hull
People also viewed
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Wayne Hull in United States
-
Wayne Hull
-
Wayne Hull
Chief Executive Officer at Iron Gate Construction
-
Wayne Hull
Director of Contracts at HighPoint Digital, Inc.
-
Wayne Hull
Logistics Manager at Union Pacific Railroad
24 others named Wayne Hull in United States are on LinkedIn
See others named Wayne Hull